Laura Puyol Selected Research

Infections

1/2022	Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
11/2021	Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain.
11/2021	Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain.
11/2021	Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).
1/2021	SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
1/2013	Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure.
5/2012	Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case-control study.
2/2012	Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children.
1/2012	Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children.
8/2011	Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Puyol Research Topics

Disease

10	Infections 01/2022 - 08/2011
9	Malaria 01/2013 - 06/2008
5	COVID-19 01/2022 - 01/2020
1	Human Influenza (Influenza) 01/2022
1	Asymptomatic Infections 11/2021
1	Common Cold 01/2021
1	Reinfection 01/2013
1	Hepatitis B 08/2011
1	Coinfection 06/2008

Drug/Important Bio-Agent (IBA)

10	AntibodiesIBA 01/2022 - 09/2009
9	Immunoglobulin G (IgG)IBA 01/2022 - 09/2009
5	VaccinesIBA 01/2022 - 09/2009
3	Immunoglobulin A (IgA)IBA 11/2021 - 01/2021
3	AntigensIBA 11/2021 - 02/2012
3	CytokinesIBA 01/2013 - 05/2012
2	Immunoglobulin M (IgM)IBA 11/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2013
2	Interleukin-10 (Interleukin 10)IBA 01/2013 - 01/2012
2	Interleukin-8 (Interleukin 8)IBA 01/2013 - 01/2013
2	Interleukin-12 (IL 12)IBA 01/2013 - 01/2012
2	Interleukin-2 (IL2)IBA 01/2013 - 01/2013
1	Indicators and Reagents (Reagents)IBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	ChemokinesIBA 01/2013
1	SuspensionsIBA 01/2013
1	Biomarkers (Surrogate Marker)IBA 01/2013
1	Interleukin-4 (Interleukin 4)IBA 01/2013
1	Interleukin-6 (Interleukin 6)IBA 01/2013
1	Interleukin-5 (Interleukin 5)IBA 01/2013
1	Merozoite Surface Protein 1 (MSA1)IBA 02/2012
1	insulin receptor-related receptor (IRR)IBA 02/2012
1	Interleukin-13IBA 01/2012
1	Interleukin-17 (Interleukin 17)IBA 01/2012
1	Malaria VaccinesIBA 08/2011
1	ImmunosorbentsIBA 09/2009
1	EnzymesIBA 09/2009
1	Codon (Codons)IBA 06/2008
1	pyrimethamine drug combination fanasil (Fansidar)FDA Link 06/2008